Cite
Schiff BA, McMurphy AB, Jasser SA, et al. Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer. Clin Cancer Res. 2019;25(15):4862doi: 10.1158/1078-0432.CCR-19-2052.
Schiff, B. A., McMurphy, A. B., Jasser, S. A., Younes, M. N., Doan, D., Yigitbasi, O. G., Kim, S., Zhou, G., Mandal, M., Bekele, B. N., Holsinger, F. C., Sherman, S. I., Yeung, S. C., El-Naggar, A. K., & Myers, J. N. (2019). Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(15), 4862. https://doi.org/10.1158/1078-0432.CCR-19-2052
Schiff, Bradley A, et al. "Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 25,15 (2019): 4862. doi: https://doi.org/10.1158/1078-0432.CCR-19-2052
Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN. Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer. Clin Cancer Res. 2019 Aug 01;25(15):4862. doi: 10.1158/1078-0432.CCR-19-2052. PMID: 31371312.
Copy
Download .nbib